Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Setting up an efficient and reliable screening method for novel c-Jun N-terminal kinase substrates

Authors: T Kallunki, C Holmberg, M Lerdrup-Hansen, T Herdegen, A Aronheim, M Jäättelä

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

The c-Jun N-terminal kinase (JNK), also known as the stress activated protein kinase (SAPK), forms a family of serine-threonine kinases that can be efficiently activated by both mitogenic and apoptotic signals. Moreover in various cases JNK activation has been shown to have both preventative and causative roles in apoptosis. Thus far the best characterized target of JNK is c-Jun, which forms a part of the transcription factor AP-1. It is a well established fact that the activation of JNKs in the cell will lead to the phosphorylation of Ser63 and Ser73 at the c-Jun activation domain. This in turn results in the transcriptional activation of the AP-1 responsive genes. We show here that, in some cancer cell lines, JNK activation does not always correlate with AP-1 activation. This lack of AP-1 activation is also associated with the lack of the phosphorylation of c-Jun. We have been testing two different 'substrate screening systems' in order to find novel, relevant JNK substrates from these cancer cells. …
Metadata
Title
Setting up an efficient and reliable screening method for novel c-Jun N-terminal kinase substrates
Authors
T Kallunki
C Holmberg
M Lerdrup-Hansen
T Herdegen
A Aronheim
M Jäättelä
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr168

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Meeting abstract

REAL Real-Time!

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine